What CJC-1295/ipamorelin is
CJC-1295/ipamorelin is two peptides sold together in one vial. Neither is a component of an FDA-approved drug, so no approved label says how much of each a vial holds. Yours says it on its own label, and that's what counts.
CJC-1295 is a synthetic peptide of 29 amino acids, an analogue of growth hormone releasing hormone (GHRH). FDA's review gives the formula of the free base as C152H252N44O42 and its molecular weight as 3367.95 g/mol. The name covers more than one substance. CJC-1295 DAC is the same peptide with an extra unit added at one end, with the formula C165H269N47O46 and a molecular weight of 3647.95 g/mol. FDA calls the two different active moieties, which it says aren't interchangeable. It also says there appear to be inconsistent naming conventions for CJC-1295, and calls that a safety risk, because a patient may be dosed with a different substance than the one ordered.
Ipamorelin is a peptide of five amino acids, some of them not found in nature. FDA's review gives the formula of the free base as C38H49N9O5 and its molecular weight as 711.85 g/mol.
Where it stands with the FDA
Neither peptide is approved by the FDA, and the agency says neither is a component of any FDA-approved drug. Both reached the FDA through nominations asking for them to be allowed in compounded drugs. FDA reviewed each one on its own, not as a blend.
The CJC-1295 nominations were withdrawn, and FDA reviewed five forms of it on its own initiative, with and without DAC, for growth hormone deficiency. Its review says the criteria weigh against putting any of them on the list of substances pharmacies may compound with. Its reasons include that none of the five was well characterized, and concern about immune reactions to an injection under the skin. On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted on each form. For CJC-1295 free base, nobody voted in favor and 13 voted against. For CJC-1295 acetate, one voted in favor and 12 against. For each of the three DAC forms, nobody voted in favor and 13 voted against.
FDA reviewed ipamorelin for two uses, growth hormone deficiency and the slowed bowel that can follow surgery, and its review says the criteria weigh against putting it on that list too. On October 29, 2024, the committee voted on it. For both the free base and the acetate, nobody voted in favor, 12 voted against and one member abstained.
FDA also keeps a page on compounding substances that may present significant safety risks. It lists both CJC-1295 and ipamorelin acetate among the substances that were in category 2 before their nominators withdrew them, and it still lists ipamorelin acetate in category 2 under section 503B, added September 29, 2023.
Of CJC-1295, that page says FDA has identified serious adverse events including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited. Of ipamorelin acetate, it says a study in the literature identified serious adverse events including death when ipamorelin was given intravenously for improving gastric motility. FDA's ipamorelin review says it's unclear whether the two deaths in that study were related to ipamorelin.
Neither name appears in FDA's list of substances nominated under section 503A, as updated May 14, 2026.
What the FDA's record says about the blend
FDA didn't review the blend, but both reviews ran into it. The CJC-1295 review says several websites recommend using CJC-1295 with ipamorelin. That's FDA describing what the websites say. It isn't a finding of its own.
On how the pair is sold, the CJC-1295 review found websites marketing CJC-1295 without DAC, form not provided, as several multi-ingredient powders, including one of CJC-1295 with ipamorelin. It also found a CJC-1295 and ipamorelin powder for which neither the form of the CJC-1295 nor whether it was with or without DAC was provided. The ipamorelin review found a compounding pharmacy's website offering the two in one vial.
FDA's record names amounts for a few of those listings. This page leaves them out, because a listing doesn't tell you what your vial holds.
FDA evaluated CJC-1295 as an injection under the skin at 2,000 mcg/mL, and the product in the ipamorelin nominations was a 2,000 mcg/mL lyophilized powder for the same kind of injection. For CJC-1295, the review says the free base reportedly has limited solubility in water, so it may not be possible to make an injection at 2 mg/mL. For ipamorelin, it says the free base has limited solubility in water and it's unclear how a 2 mg/mL injection could be made. The reviews describe the acetate of each as soluble in water at 5 mg/mL.
Storing CJC-1295/ipamorelin
FDA's reviews say that, as reported in the literature, CJC-1295 free base is expected to be stable stored below -20°C and ipamorelin below -18°C. The ipamorelin review repeats a report that the lyophilized free base is stable at room temperature for three weeks, and adds that it's recommended to be stored desiccated below -18°C all the same. All of that describes one peptide on its own, not a blend.
The CJC-1295 review adds that how stable a peptide stays depends heavily on how the finished product was made.
There's no approved label for either peptide or for the blend, so no label says how long a mixed vial keeps.
CJC-1295 and Ipamorelin dosage calculator questions
How do I turn a CJC-1295/ipamorelin dose into syringe units?
Pick the peptide your dose is of, divide that dose by that peptide's concentration to get millilitres, then multiply by 100. The same draw carries the others along in proportion. A vial with 5 mg of CJC-1295 and 5 mg of Ipamorelin mixed with 2 mL holds 2.5 mg/mL of CJC-1295 and 2.5 mg/mL of Ipamorelin, so ten units hold 250 mcg of CJC-1295 and 250 mcg of Ipamorelin.
How much bacteriostatic water goes in a CJC-1295/ipamorelin vial?
There's no single right amount. The water sets the concentration of every peptide in the vial at once, and changes none of the amounts. Choose the amount that puts your dose somewhere between about 10 and 40 units, where it's easiest to read.
Is CJC-1295/ipamorelin approved by the FDA?
No. FDA says neither CJC-1295 nor ipamorelin is a component of any FDA-approved drug. Its advisory committee voted against allowing ipamorelin in compounded drugs on October 29, 2024, and against every form of CJC-1295 on December 4, 2024.
Does this page tell me how much CJC-1295/ipamorelin to take?
No. There's no FDA-approved product with either peptide in it, so there's no approved dose to point to. The dose box starts empty for that reason, and the chart only converts.
How much of each peptide is in a CJC-1295/ipamorelin vial?
Whatever its label says. No approved label sets the amounts, so this page can't know them. The vial in the first question is only an example. Type in the two amounts from your own label.
Which peptide do I enter my dose for?
Whichever one your dose is written in. Choose it under "The dose is of". The draw is one liquid, so it carries the other peptide along in a fixed proportion, and the page shows how much of each your draw holds.
Does it matter whether the CJC-1295 has DAC?
Not to the arithmetic, which only counts milligrams. It matters to what's in the vial. FDA's review treats CJC-1295 and CJC-1295 DAC as different active moieties that aren't interchangeable, and says the naming appears to be inconsistent. Go by what your label says.
More peptide calculators by name
The same instrument, set up one peptide at a time. For any other vial, use the peptide reconstitution calculator.